VAL-083 (GBM) - VAL-083 targets Glioblastoma Multiforme (GBM), a market with >$800 million growing to $14 billion in 2027[5] - Kintara's VAL-083 is the only drug currently participating in all three GBM patient subtypes in the GBM AGILE trial[14] - In newly-diagnosed patients, VAL-083 showed a median Progression Free Survival of 87 months (SYSUCC) and 100 months (MDACC), compared to a TMZ historical comparator of 53-69 months[7] - In recurrent patients, VAL-083 showed a median Overall Survival of 79 months, compared to a Lomustine historical comparator of 72 months[8] - Kintara initiated patient randomization in the GBM AGILE trial for VAL-083 as of January 6, 2021[14] REM-001 (CMBC) - REM-001 targets Cutaneous Metastatic Breast Cancer (CMBC), representing a ~$500 million market opportunity[3, 16] - Prior clinical trials of REM-001 showed an 80% complete response rate in 674 evaluable lesions[17] - The company anticipates starting a lead-in study for CMBC in Q4 2021 / Q1 2022[18] General - The company estimates a combined investment of $240 million in R&D to date supporting its products[3] - Kintara has multiple US/EU Orphan Drug and Fast Track Designations for its products[27]
Kintara Therapeutics (KTRA) Investor Presentation - Slideshow